NCT05498896View on ClinicalTrials.gov

Investigate the Contribution of Ipatasertib to Neoadjuvant Chemotherapy Plus Atezolizumab in TNBC

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

146

Participants

Timeline

Start Date

December 19, 2018

Primary Completion Date

January 29, 2021

Study Completion Date

January 30, 2026

Conditions
Triple Negative Breast Cancer
Interventions
DRUG

Atezolizumab

IV infusion

DRUG

Ipatasertib

Oral

DRUG

Paclitaxel

IV infusion

DRUG

Doxorubicin

IV infusion

DRUG

Cyclophosphamide

IV infusion

Trial Locations (1)

Unknown

Barts Health NHS Trust, London

All Listed Sponsors
collaborator

Westdeutsche Studiengruppe GmbH (WSG)

UNKNOWN

collaborator

MedSIR

OTHER

collaborator

Hoffmann-La Roche

INDUSTRY

lead

Queen Mary University of London

OTHER

NCT05498896 - Investigate the Contribution of Ipatasertib to Neoadjuvant Chemotherapy Plus Atezolizumab in TNBC | Biotech Hunter | Biotech Hunter